$6.88
-0.01-0.15%
Last update: Nov 11, 4:38 PM
Cartesian Therapeutics Inc
RNACNASDAQ
Cartesian Therapeutics fell 9.2% from $7.58 to $6.88, behind the S&P 500's +11.2%. Its worst day was Mar 5 (−12.6%), and its low came Jun 5 at $5.84.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Cartesian Therapeutics shares rose 17.6%, while the S&P 500 fell 0.1%.
+17.6% · S&P 500 −0.1%
EPS of $-1.39 missed the $-0.80 estimate on $947,000.00 revenue (est. $212,132.00).
+31.7%, the year's best day · S&P 500 +0.9%
Story events cover the past 12 months · Times ET
EPS of $-1.46 missed the $-0.73 estimate on $78,000.00 revenue (est. $205,912.00).
−3.9% · S&P 500 +1.0%
Cartesian Therapeutics closed at its lowest level of the year, 23.0% below where the year started.
−10.8% · S&P 500 −2.6%
Cartesian Therapeutics closed at its highest level of the year, 39.7% above where the year started.
+4.0% · S&P 500 −0.1%
EPS of $0.46 beat the $-0.68 estimate on $0.00 revenue (est. $162,912.00).
+4.9% · S&P 500 −0.2%
Cartesian Therapeutics shares rose 14.0%, while the S&P 500 rose 0.2%.
+14.0% · S&P 500 +0.2%
EPS of $-0.38 beat the $-1.01 estimate on $0.00 revenue (est. $147,144.00).
−0.6% · S&P 500 −4.4%
Where it ended: a close of $6.88 on Nov 11, 2026. Up next: Q4 2026 earnings on Mar 8, 2027 (EPS est. $-0.99, revenue est. $261,432.00).
Nothing in the past 12 months.
All RNAC dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RNAC and SPY from Benzinga historical bars. Not investment advice.
